Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Accumulated Expenses (2022 - 2025)

Mangoceuticals' Accumulated Expenses history spans 4 years, with the latest figure at $9421.0 for Q4 2025.

  • On a quarterly basis, Accumulated Expenses changed N/A to $9421.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $9421.0, a N/A change, with the full-year FY2025 number at $9421.0, changed N/A from a year prior.
  • Accumulated Expenses hit $9421.0 in Q4 2025 for Mangoceuticals, up from $4460.0 in the prior quarter.
  • Over the last five years, Accumulated Expenses for MGRX hit a ceiling of $9421.0 in Q4 2025 and a floor of $2717.0 in Q4 2022.
  • Historically, Accumulated Expenses has averaged $5762.3 across 4 years, with a median of $5580.0 in 2024.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 142.73% in 2023 and later crashed 36.57% in 2025.
  • Tracing MGRX's Accumulated Expenses over 4 years: stood at $2717.0 in 2022, then skyrocketed by 142.73% to $6595.0 in 2023, then fell by 15.39% to $5580.0 in 2024, then skyrocketed by 68.84% to $9421.0 in 2025.
  • Business Quant data shows Accumulated Expenses for MGRX at $9421.0 in Q4 2025, $4460.0 in Q3 2025, and $2973.0 in Q2 2025.